Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, Gandhi M, Di Federico A, Pecci F, Wang X, Makarem M, Hidalgo Filho CM, Gorria T, Saini A, Pabon C, Lindsay J, Pfaff KL, Welsh EL, Nishino M, Sholl LM, Rodig S, Kilickap S, Rietschel P, McIntyre DA, Pouliot JF, Altan M, Gainor JF, Heymach JV, Schoenfeld AJ, Awad MM. Ricciuti B, et al. Among authors: kilickap s. JTO Clin Res Rep. 2024 Apr 12;5(9):100675. doi: 10.1016/j.jtocrr.2024.100675. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39399157 Free PMC article.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Özgüroğlu M, et al. Among authors: kilickap s. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. Lancet Oncol. 2023. PMID: 37591293 Clinical Trial.
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Kahraman S, Karakaya S, Kaplan MA, Goksu SS, Ozturk A, Isleyen ZS, Hamdard J, Yildirim S, Dogan T, Isik S, Celebi A, Gulbagci BB, Paksoy N, Dogan M, Turk HM, Bilici A, Tatli AM, Akbas S, Turan N, Hacibekiroglu I, Dogu GG, Aydiner A, Sumbul AT, Akyurek S, Yalciner M, Demirkazik A, Gursoy P, Aykan MB, Sahin E, Karadag İ, Kostek O, Er MM, Artaç M, Duzkopru Y, Aydin D, Isik D, Karakas Y, Kilickap S, Erol C, Demir B, Civelek B, Ergun Y, Akinci MB, Dogan I, Karadurmus N, Yumuk PF, Sendur MAN. Kahraman S, et al. Among authors: kilickap s. Sci Rep. 2024 Mar 9;14(1):5820. doi: 10.1038/s41598-024-56046-w. Sci Rep. 2024. PMID: 38461209 Free PMC article.
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, Wu L, Wang X, Viguro M, Makharadze T, Sun H, Luo F, Shi J, Zang A, Pan Y, Chen Z, Jia Z, Kuchava V, Lu P, Zhang L, Cheng Y, Kang W, Wang Q, Yu H, Li J, Zhu J; ASTRUM-004 Investigators. Zhou C, et al. Among authors: kilickap s. Cancer Cell. 2024 Feb 12;42(2):198-208.e3. doi: 10.1016/j.ccell.2023.12.004. Epub 2024 Jan 4. Cancer Cell. 2024. PMID: 38181795 Clinical Trial.
Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.
Karadurmus N, Kaplan MA, Sendur MAN, Urun Y, Demirci U, Karaca SB, Goktas Aydin S, Aykan MB, Bilici A, Sezer A, Yilmaz U, Abali H, Yumuk PF, Degirmencioglu S, Demirkazik A, Paydas S, Mirili C, Turna H, Kargi A, Ozdogan M, Guven DC, Ozguroglu M, Kilickap S. Karadurmus N, et al. Among authors: kilickap s. Curr Med Res Opin. 2024 Jul;40(7):1171-1178. doi: 10.1080/03007995.2024.2359026. Epub 2024 Jun 22. Curr Med Res Opin. 2024. PMID: 38809230
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Peters S, et al. Among authors: kilickap s. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19. Nat Med. 2024. PMID: 38898120 Free PMC article. Clinical Trial.
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
Arak H, Erkiliç S, Yaslikaya Ş, Eylemer Mocan E, Aktaş G, Özdemir M, Semiz HS, Kiliçkap S, Özalp FR, Sever ÖN, Akdağ G, Ağaoğlu AB, Özçelik M, Sari M, Arcagök M, Anik H, Yayla ŞB, Sever N, Açar FP, Bayrakçi İ, Turhal S, Ayhan M, Kuş T; Turkish Oncology Group Study. Arak H, et al. Among authors: kilickap s. J Immunother. 2024 Jun 1;47(5):182-189. doi: 10.1097/CJI.0000000000000508. Epub 2024 Mar 11. J Immunother. 2024. PMID: 38333962 Free PMC article.
245 results